Nextar Chempharma Solutions
Contract Drug Development and Manufacturing
Company Overview
Snapshot
Founded in July 2007 by Orna Dreazen, Nextar Chempharma Solutions operates with 11–50 employees. The company has raised $370,000 across one funding round. In March 2025, Nextar Chempharma Solutions merged with Nextage Therapeutics.
Business overview
Nextar Chempharma Solutions specializes in the development and manufacturing of drugs and medical devices, focusing on contract services. The company's core technology is its proprietary Brain Targeted Liposomes (BTLS) platform, designed to facilitate the targeted delivery of various drugs across the blood-brain barrier and into the brain. This platform combines a liposomal vehicle with a targeter complex to enable brain-specific permeation of therapeutic agents. Nextar serves the pharmaceutical and life sciences industries, operating within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Drugs Discovery & Development.
Strategic signal
In September 2023, Nextar Chempharma Solutions announced positive final results from a mouse study demonstrating the efficacy of its BTLS platform for treating glioblastoma, a type of brain cancer. This preclinical validation of its core drug delivery technology signals significant progress in addressing challenging neurological conditions and could accelerate future therapeutic development and partnerships, indicating strong potential for its brain-targeted drug delivery capabilities.
Log in to access full profile ›Company Intelligence Q&A
- What is Nextar Chempharma Solutions' primary focus?
- Nextar Chempharma Solutions specializes in contract drug development and manufacturing, with a particular focus on its Brain Targeted Liposomes (BTLS) platform for targeted drug delivery to the brain.
- When was Nextar Chempharma Solutions founded?
- Nextar Chempharma Solutions was founded in July 2007.
- What significant corporate event occurred in March 2025?
- In March 2025, Nextar Chempharma Solutions merged with Nextage Therapeutics. The merger agreement was signed in September 2023, valuing Nextar at no less than 78 million NIS.
- What was the outcome of the glioblastoma study in September 2023?
- In September 2023, Nextar Chempharma Solutions reported positive final results from a mouse study demonstrating the efficacy of its BTLS platform for treating glioblastoma.
- What was the total capital raised by Nextar Chempharma Solutions?
- Nextar Chempharma Solutions raised $370,000 across one funding round.